Key result
Combined treatment with empagliflozin and the ALDH2 activator Alda-1 improved exercise tolerance, diastolic function, and cardiac remodeling in a mouse model of diabetes-associated HFpEF more effectively than empagliflozin alone.
Why the study?
Hyperglycemia-induced 4HNE accumulation is critical for diabetes-mediated cardiotoxicity, prompting evaluation of whether lowering 4HNE ameliorates diabetes-associated HFpEF.
Does the combination of empagliflozin and Alda-1 improve cardiac function and exercise tolerance in a mouse model of diabetes-associated HFpEF?
Does the combination of empagliflozin and Alda-1 improve cardiac function and exercise tolerance in a mouse model of diabetes-associated HFpEF?
Combining an SGLT2 inhibitor with an ALDH2 activator synergistically improves cardiac function and reduces oxidative stress in a preclinical model of diabetes-associated HFpEF.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ALDH2 activation plus SGLT2 inhibition in diabetes-associated HFpEF; human trials needed before any clinical consideration.
Objectives: To ameliorate diabetes mellitus associated heart failure with preserved ejection fraction (HFpEF), we plan to lower diabetes-mediated oxidative stress-induced 4-hydroxy-2-nonenal (4HNE) accumulation by pharmacological agents that either decrease 4HNE generation or increase its detoxification. Background: 4HNE, a cellular reactive carbonyl species (RCS), was significantly increased in diabetic hearts due to a diabetes-induced decrease in 4HNE detoxification by aldehyde dehydrogenase (ALDH)2, a cardiac mitochondrial enzyme that metabolizes 4HNE. Therefore, hyperglycemia-induced 4HNE is critical for diabetes-mediated cardiotoxicity and we hypothesize that lowering 4HNE ameliorates diabetes associated HFpEF. Methods: We fed high-fat diet to ALDH2*2 mice which have intrinsically low ALDH2 activity to induce type-2 diabetes. After 4 months of diabetes, the mice exhibited features of HFpEF and along with increased 4HNE adducts and we treated them with vehicle, empagliflozin (EMP) (3mg/kg/d) to reduce 4HNE and Alda-1 (10mg/kg/d), an ALDH2 activator to enhance ALDH2 activity as well as a combination of EMP + Alda-1 (E + A), via subcutaneous osmotic pumps. After 2 months of treatments, cardiac function was assessed by conscious echocardiography before and after exercise stress. Results: EMP + Alda-1 improved exercise tolerance, diastolic and systolic function, 4HNE detoxification and cardiac liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway in ALDH2*2 mice with diabetes associated HFpEF. This combination was even more effective than EMP alone. Conclusions: Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes associated HFpEF.
No takes yet. Share an insight, caveat, or question.
Palaniyandi et al. (2022) studied Diabetes associated heart failure with preserved ejection fraction (HFpEF) (n=40). Empagliflozin and Alda-1 vs. Vehicle, Empagliflozin alone, or Alda-1 alone was evaluated on Cardiac function and exercise tolerance. Combined treatment with empagliflozin and the ALDH2 activator Alda-1 improved exercise tolerance, diastolic function, and cardiac remodeling in a mouse model of diabetes-associated HFpEF more effectively than empagliflozin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: